You said it well hschlauch. Now we wait for the Institutions to wake up and start accumulating shares of $ONCS. Good luck to all of us shareholders that have the patience and resolve.
The abstract for the multi-gene construct at SITC next month is titled "Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model"
....being as this is a mouse study do you think positive results which are implied by the abstract title is enough to move the needle at this early stage. I really hope this additional data on top of the current combo study update will finally get a lot more institutions to jump on board here.... and instill more confidence in the stock.
Good post. Just curious, what is the difference between the multigene construct and the DMAB of INO? Are there any overlap between the 2 technology? Thanks
News 
Market Data 
Discover 
AI
